• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

UTUC therapy yields high rate of disease eradication, durability

Article

In this video, Seth P. Lerner, MD, discusses the OLYMPUS Trial of intracavitary UGN-101 (mitomycin gel; Jelmyto) in patients with low-grade upper tract urothelial carcinoma.

In patients with low-grade upper tract urothelial carcinoma, treatment with intracavitary UGN-101 (mitomycin gel; Jelmyto) resulted in a high rate of disease eradication that was found to be durable in a majority of patients, results of the OLYMPUS Trial showed. In this interview, senior author Seth P. Lerner, MD, discusses the study’s efficacy and tolerability data and where this therapy fits into the current treatment paradigm. Lerner was interviewed by Urology Times® Editorial Consultant J. Brantley Thrasher, MD. Disclosure: The OLYMPUS Trial was funded by UroGen Pharma.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.